This preparation is commonly used for managing symptoms associated with acute or chronic conditions such as rhinitis, catarrh, and certain forms of sinusitis where patients may experience symptoms related to nasal congestion and the production of profuse or purulent mucus. It provides symptomatic support which may assist with easing the symptom burden of a runny nose and contributes to easing symptoms related to inflammatory or irritative states that interfere with daily functioning.

The preparation is commonly used within therapeutic areas involving heightened responses, relevant in clinical settings for symptomatic relief in conditions including tonsillitis and stomatitis. This supportive relief is applicable within clinical settings that involve acute or unstable symptom patterns, especially when symptoms cluster into patterns involving purulent discharge. In these instances, the use of this preparation is associated with assisting with managing conditions involving inflammatory or irritative processes, and supports the patient during difficult episodes by easing distress during periods of heightened symptomatic distress.

“This preparation is relevant for managing symptom clusters that may become intense or disruptive.”

---

Quick Fact: Relief for Mucosal Symptoms
Symptoms: Symptoms related to inflammatory or irritative states, including nasal congestion and symptoms related to physical discomfort from discharge.
Clinical Context: Relevant in conditions characterized by periods of heightened symptoms, commonly used to help with acute and chronic rhinitis, catarrh, and certain rhinosinusitis symptoms in both adults and children.

---

Eligibility Profile: Who Can and Cannot Use Сиалор?

This section outlines the official eligibility and non-eligibility criteria for using the medicine Сиалор (active ingredient: Silver Protein/Protargol), as defined by its regulatory labeling.

Eligibility Status	Population Criteria	Regulatory Classification
Contraindicated (Must Not Use)	Known hypersensitivity or allergy to Silver Protein or any other excipients in the formulation.	Absolute Contraindication
Contraindicated (Must Not Use)	Pregnancy or the period of breastfeeding (lactation).	Physiological State Contraindication
Contraindicated (Must Not Use)	Patients diagnosed with atrophic rhinitis.	Condition-Specific Contraindication
Contraindicated (Must Not Use)	Pediatric patients below the age of 3 years.	Age-Related Contraindication
Allowed	The general population above 3 years of age who do not meet any of the contraindication criteria.	General Eligibility

Official regulatory documents strictly define the user population by establishing clear contraindications. Use of the medicine is prohibited for individuals with a known allergy to its components, and for women who are pregnant or nursing. Furthermore, a firm exclusion is placed on children under three years old and on patients with the specific nasal condition of atrophic rhinitis. These conditions are explicitly stated in the official regulatory documentation and form the basis of the drug's approved eligibility profile.

Interactions with other medicines and products

The interaction profile for Silver Proteinate (Сиалор) is determined by its strictly topical application as an antiseptic and astringent agent for the nasal mucosa. Regulatory documentation confirms that the drug is not systemically absorbed, which directly impacts the classification of potential interactions.

---

Interaction Scope and Classification

Absence of Systemic Interactions

• No systemic pharmacokinetic interactions are documented. Silver Proteinate does not participate in enzyme-mediated metabolism, meaning it does not act as a substrate, inhibitor, or inducer of Cytochrome P450 enzymes.
• The absence of systemic exposure eliminates concerns for transporter-mediated interactions (e.g., P-gp) and the need for population-specific interaction adjustments related to systemic impairment.
• No interactions are documented with food, alcohol, or herbal products, which aligns with the non-systemic route of administration.

Local Chemical Incompatibility and Restriction

• The primary documented interaction is a local chemical incompatibility with other substances administered to the nasal mucosa.
• Co-administration with topical products containing halide salts, iodides, or organic acids can result in the physical precipitation or chemical inactivation of Silver Proteinate at the site of administration.
• This incompatibility leads to a mandatory temporal separation rule: a time interval must be strictly observed between the use of Сиалор and any other local nasal or topical preparation to prevent the local interaction.

How Сиалор Works

Сиалор's mechanism of action is entirely local, driven by the Ag^+ ion released from the proteinate complex, resulting in two distinct and simultaneous physiological effects at the mucosal surface.

---

U0001f9a0 Microbial Enzyme Inactivation

This domain describes the primary antiseptic mechanism where the Ag^+ ion acts as an irreversible inhibitor. It targets and binds chemically to the sulfhydryl ( SH) groups on essential microbial enzymes and structural proteins. This denaturation and inactivation of key molecular machinery interrupts microbial metabolism and cell function, leading to a reduction of the surface microbial load.

---

U0001f6e1️ Local Surface Protein Precipitation

This domain details the astringent mechanism. The silver ion causes the precipitation and coagulation of superficial proteins on the host's inflamed mucous membrane, creating a thin, protective film. This physicochemical process stabilizes the tissue surface structure, leading to a direct reduction in the local exudation and discharge of fluid from the membrane.

---

⏱️ Formulation and Mechanistic Constraints

The proteinate component functions as a controlled-release matrix, modulating the rate at which the active Ag^+ ion becomes available. This sustained release is a functional requirement for the sustained presence of the active ion on the mucosal surface, which dictates the time-dependent nature of the physiological effects. However, the mechanism is limited by the presence of organic material (e.g., mucus, pus) or salts, which can chemically bind the Ag^+ ion and reduce its activity against the intended microbial and tissue targets.

Administration Guidelines for Silver Proteinate

Silver Proteinate (Сиалор, Protargol) is strictly intended for topical application. Its use is localized to the mucous membranes of the head, primarily administered as drops into the nostril (intranasal) or the ear canal (intra-aural).

---

Dosing and Preparation Requirements

Usage Parameter	General Usage Parameters
Pharmaceutical Form	Supplied as a powder for solution.
Preparation	Must be accurately reconstituted with purified water prior to use.
Adult Single Dose	1 to 2 drops per application into the affected cavity.
Frequency	Applied 2 to 3 times a day.
Duration	Restricted to a short-term course of 5 to 10 days.

---

Population and Procedural Rules

Use of Silver Proteinate is defined by the strength of the solution and the patient's age. For pediatric patients (specifically children from birth up to 3 years of age), the 0.5% solution strength is the conventionally designated form, while the stronger 1% and 2% solutions are available for older children and adults.

The standard protocol requires the accurate preparation of the solution before use, followed by the measured instillation of drops into the target area, repeated daily. The medicine's label specifies that its topical use should not be concurrent with local preparations containing the enzyme papain or certain other compounds.

Research Evidence / Overview of Studies for Сиалор

Evidence for Use in Acute Infectious Rhinitis (Common Cold)

Research has explored the use of Silver Proteinate in conditions associated with acute or disruptive episodes, such as the common cold, particularly in children. Studies conducted during periods of increased symptom activity have primarily used non-blinded, comparative trial designs. These trials have monitored short-term symptom changes, with researchers examining patient-reported experiences related to outcomes linked to inflammatory or irritative states, such as a runny nose and congestion.

In these research scenarios, studies report how symptoms evolved in the observed pediatric populations. Findings describe patterns observed in the studies related to the overall duration of symptoms and the time needed for symptoms to evolve. However, the evidence contributing to this understanding is often derived from smaller, localized settings. The studies often focused on a general assessment of changes in condition rather than using the standardized, single-symptom measurement scales common in larger international trials.

Evidence for Use in Chronic Sinus Conditions

Research has examined more complex, chronic situations where Silver Proteinate was observed, specifically in adult patients with medically recalcitrant or refractory chronic rhinosinusitis (CRS). Studies have been conducted during periods of increased symptom activity, using approaches such as small-scale comparative trials and Randomized Crossover Trials (RCTs). Researchers examined outcomes related to physical discomfort using validated symptom questionnaires, such as the Sino-Nasal Outcome Test-22 (SNOT-22), and objective measures like Endoscopic Scores.

Research has examined short-term symptom changes. Findings reported patterns related to changes in SNOT-22 and Visual Analog Scale (VAS) scores, which are patient-reported outcomes describing perceived discomfort. However, the data show patterns related to trials where statistically significant differences were not observed on primary outcome measures when compared against control or placebo groups.

What Is Still Uncertain About Сиалор Research

The overall research landscape is marked by several limitations, leading to a general Low Evidence Level across the studied conditions. The evidence quality varies across studies, with many trials characterized by modest sample sizes. Research findings reflect the populations studied in the limited clinical trials, meaning the findings describe group patterns, not individual outcomes, and may not be broadly generalizable.

Follow-up durations were limited, making long-term effects not fully established. Additionally, comparative evidence is lacking against many standard or widely accepted treatments. Research provides context but highlights what is known — and what is still uncertain — regarding the full scope of this preparation's effects.

Key Studies & References

1. Anti-Inflammatory Effect of Nano-Silver in Chronic Rhinosinusitis Mouse Model

Common questions about Сиалор (FAQ)

---

Q: Is it safe to take this medication while pregnant?

According to official product information, the use of this medication during pregnancy has been an area of study, particularly concerning prolonged use. The consideration of using this medicine, weighing potential benefits against potential risks during pregnancy, is a matter for discussion with a healthcare provider.

---

Q: What is the correct way to store this medicine?

Regulatory documents state that the product should be stored at room temperature, typically within the range of 68 F to 77 F (20 C to 25 C). The product information states the medicine should be protected from excessive heat and moisture, and kept out of the reach of children.

---

Q: Can children under 2 years old use this product?

Official labeling provides specific dosing directions for children aged 2 years and older. For children under 2 years of age or weighing less than 24 lbs (11 kg), product labeling specifies that a healthcare provider should be consulted.

---

Q: Is this product safe for long-term daily use?

Regulatory warnings typically include caution regarding extended periods of use. The regulatory documents state that if pain lasts for more than 5 days or fever lasts for more than 3 days, one should cease use and seek assistance from a healthcare professional. Official information advises using the lowest effective dose for the shortest duration necessary.

---

Q: Does this medication cause drowsiness or affect my ability to drive?

Official information does not commonly cite the main active ingredient in this product as a cause of drowsiness. However, if the product contains other ingredients, such as an antihistamine, the official label may include a warning about potential drowsiness and the need for caution when performing tasks requiring full alertness, such as driving or operating machinery.

---

Q: What happens if I take it with alcohol?

The official label includes a Stomach Bleeding Warning associated with the use of the medicine. The product label specifies that individuals who consume 3 or more alcoholic drinks every day should consult a doctor or pharmacist prior to use.

How to Store and Dispose of Сиалор?

The storage and disposal of Сиалор (Silver Proteinate) is governed by specific regulatory mandates to maintain its stability and ensure environmental safety.

Storage Requirements

The unmixed powder must be stored in its original container at a temperature not exceeding 25 C in a cool, dry place. The container must be kept tightly closed and protected from light and moisture. After reconstitution, the prepared solution is time-sensitive and should be discarded after a maximum of 15 days.

Disposal Instructions

Official instructions require the product to be kept out of the sight and reach of children. Unused or expired Сиалор must not be released into the environment; disposal into the sanitary sewer system or surface water is strictly forbidden. All discarded material must be handled and disposed of in compliance with local regulations.